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IV 
ABSTRACT 
JOSHUA DANIEL DOLSEN: O-GlcNAcylation of HIF-1α Protein in Human Breast 
Cancer Cells 
 Cancer is an insidious disease that, if not caught in time, can cause devastating 
effects on the human body, especially if it metastasizes. It is important to note that each 
cancer behaves and develops differently based on its location in the body and the cellular 
characteristics constitute the instance of the disease. However, the development of cancer 
can universally be characterized by the acquisition of different hallmark abilities that 
promote disease progression. Proteins known as hypoxia-inducible factors (HIFs) can 
influence progression through these hallmarks, but primarily provides cancer cells with the 
ability to alter its metabolism to survive and further progress in hypoxic conditions, which 
are common intratumorally. The HIF transcription factors are composed of two subunits, 
an ‘α’-subunit that is oxygen-regulated and a constitutively expressed ‘β’-subunit. 
Posttranslational modifications are a common form of regulation among cell types. 
Specifically, enhanced O-GlcNAcylation, the addition of O-linked β-N-acetylglucosamine 
(O-GlcNAc), has been observed to have implications in the progression of diseases, 
including breast cancer. The purpose of this research is to detect O-GlcNAcylation of HIF-
1α protein, using the triple negative breast cancer MDA-MB-321-derived (MDA-MB-231 
BoM) bone-specific organotropic subclone as an in vitro model. 
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1 
Introduction/Background 
Cancer is among one of one of the most common causes of death in some countries 
and has become an increasingly popular area of research. This disease does not 
discriminate and presents itself in many different forms throughout the body. Cancer is an 
umbrella term used to describe a variable set of diseases that is characterized by unusual, 
uncontrolled cell proliferation, that often spreads to neighboring tissues as it manifests. In 
cancerous cells, the cellular life cycle, replication, and apoptosis, are altered, which results 
in this abnormal, uncontrolled cell growth that frequently allows for the formation of 
tumors. Cancer cells arise from pre-existing, healthy cells (Hanahan and Weinberg, 2011). 
Healthy cells recognize and respond accordingly to cell-to-cell signaling, and 
environmental cues that allow these cells to dictate their replication and life cycle in order 
to mature, but also not cause damage. In contrast, cancerous cells disobey many of these 
signals and do not differentiate into cells that provide a specialized physiological function. 
Consequently, this can result in continuous replication of abnormal cells that often 
accumulate genomic mutations. Normal, healthy cells would be able to repair such damage 
or undergo apoptosis if the damage was permanent, but cancerous cells lack this ability. In 
contrast to normal cells, that usually reside within the tissue they are physiologically 
specialized for, cancerous cells are likely to detach and systematically travel. The 
cancerous cells that do travel throughout the body increases the severity of the disease, 
especially if a mass of cells leaves its area of origin and continues to replicate and develop 
in a process called metastasis. These primary changes in cellular characteristics are the 
result of the aggregation of mutations which either cause an overexpression of tumor-
promoting oncogenes, or a disabling or under expression of tumor suppressing genes 
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(Hanahan and Weinberg, 2011). Simply stated, the emergence of cancer is due to the 
accumulation of mutations.   
A solid foundation for understanding the biology of cancer has been established by 
what Hanahan and Weinberg call the Hallmarks of Cancer. These hallmarks describe ten 
biologically, particular and distinctive capabilities that allow for cancer cells to form 
tumors, grow these tumors, and metastasize. These capabilities are acquired during the 
multistep development of tumors and include the major abilities of proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis (Hanahan and Weinberg, 2011). Each 
can emerge independently from each other, but one or more hallmarks can induce the birth 
of another through its impact on tumor cells. In particular, one of the most foundational 
characteristics of cancerous cells is perpetuation of chronic proliferation. This is partially 
achieved either by the disabling of tumor suppressor genes, and unresponsiveness to 
contact inhibition, which can result in evading growth suppressing factors (Hanahan and 
Weinberg, 2011). Cancer cells, in opposition to normal conditions, can also deregulate the 
production and release of growth-promoting signals that dictate progression of cellular 
growth, becoming unrestricted by normal cell limitations and free from reliance on external 
growth factors (Hanahan and Weinberg, 2011). This abnormality among these cells allows 
for self-sufficiency by utilizing autocrine signaling, indelibly activating proliferative 
pathways, and deactivating negative feedback systems (Thermofisher, 2015). By acquiring 
the ability of self-proliferative signaling, and evading repressors of cell growth, tumor cells 
can obtain this unique ability of uncontrolled replication. Underlying these hallmarks, 
genome instability, chronic inflammation, reprogramming of cellular metabolism, and 
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evasion of the immune system collectively drive cancer progression (Thermofisher, 2015) 
(Hanahan and Weinberg, 2011). 
Cancer may develop anywhere in the body and is capable of forming solid tumor 
masses, or tumors that affect blood cells. In general, there are two ways to classify cancer: 
by tissue type of origin or histologic characteristics of the cancer and by primary location, 
where it first developed (National Cancer Institute, 2019). Cancer cells resemble the cells 
of tissues from which they originate; breast cancer will resemble breast tissue. Breast 
cancers can emerge in various parts of the breast. Most arise in the ducts that move milk 
from the breast lobules to the nipple, but some cancers form in the milk-producing lobules 
or rarely in the connective tissue (American Cancer Society, 2019) (Mayo Clinic, 2018). 
Initially, diagnosis of breast cancer is done through breast exams, either by touch or 
mammogram, or breast ultrasound. If cancer is suspected, a biopsy of the breast tissue 
containing the cells from the suspicious area is analyzed to confirm if they are cancerous, 
and if so, reveal cell-specific traits (Mayo Clinic, 2019). All breast cancers are not identical 
and have unique characteristics that help provide insight on behavior, course of treatment, 
and prognosis. Certain cell surface receptor types, particularly presence of receptors for 
estrogen (ER-positive) and progesterone (PR-positive) used for growth stimulation, 
indicate sensitivity to these hormones; treatment includes endocrine therapy (Mayo Clinic, 
2018). Another specific characteristic is the expression of the human epidermal growth 
factor receptor 2 (HER2) protein, which provides another therapeutic target. In contrast to 
cells that express these receptor types, triple negative breast cancer (TNBC) cells lack 
estrogen, progesterone, and HER2 receptors and are much more difficult to treat (Zhou et 
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al, 2018). Lacking these receptors results in greater difficulty when treating this specific 
type of breast cancer cell due to reduction in number of molecular targets. 
Cancers are also described based on their stage of development, denoted stage 0 
through 4. Knowing the stage at which the cancer has developed is a vital tool in treatment. 
This knowledge also allows for the development of more effective treatment methods 
(Mayo Clinic, 2018). Breast cancer progresses through these 4 stages, which respectively 
correlate to severity and invasiveness. Stage 0 breast cancer includes non-invasive, 
localized masses that show no evidence of invasion to neighboring tissues. Cancer stages 
1 through 3 involve invasive cancers that respectively spread to the neighboring lymph 
nodes. If cancerous masses are able to further develop, some cancers may reach stage 4. 
This final stage of cancer development occurs when invasive breast cancer spreads beyond 
breast tissue and nearby lymph nodes to different parts of the body (Mayo Clinic, 2018). 
Stage 4 cancer is commonly called advanced or metastasized cancer, and breast tumors at 
this stage usually spread to the brain, bone, lung, and liver (Zhou et al, 2018). Over 90% 
of all deaths due to breast cancer is due to metastasis (Gilkes and Semenza, 2013) (Muz et 
al, 2015). Due to the type of tissue breast cancer usually emerges in, approximately 0.1% 
of men will develop this disease over their lifetime based annual incidence rates (American 
Cancer Society, 2019). The 99.9% of other cases occur in females.  According to the Breast 
Cancer Research Foundation, breast cancer is the most common cancer among American 
women after skin cancer and represents one in four of all cancers among women (Breast 
Cancer Research Foundation, 2018). Due to the increasing severity and invasiveness of 
breast cancer respective to its stage, and how common the disease is in women, early 
detection is imperative.  
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As cancers develop and form masses a complex microenvironment forms at the 
tumor site. The tumor microenvironment (TME) has become recognized as a major 
promoter for tumorigenesis and disease progression, as well as a useful tool to determine 
response to treatment (Soysal et al, 2015) (Wang et al 2017). The tumor microenvironment 
is composed of the interactions between the tumor and the adjacent tissues, which 
encompasses multiple cell types, including immune cells, blood vessels, inflammatory 
cells, the extracellular matrix (ECM), and cell-signaling molecules (Chen et al, 2015). 
Normal cells involved in the TME of breast cancer include fibroblasts, leukocytes, 
adipocytes, and myoepithelial and endothelial cells (Soysal et al, 2015). These interactions 
between the tumor and the surrounding components affects how the tumor grows and 
develops by providing the cancerous mass with different tools to progress in severity.  
In particular, the tumor’s response to inflammation is a critical factor in cancer 
development. When the immune system recognizes a tumor as antigenic, the immune 
response of nearby fibroblasts and immune cells, as well as the ECM is similar to that of 
dealing with a wound. This includes, pro-inflammatory signals, aiding in angiogenesis, 
preventing apoptosis, and accelerating the cell cycle, which in union highly promotes 
tumorigenesis (TME role). Inflammation in the TME is the result of this network of 
signaling from cells in the area. Dying cells that undergo necrosis also release pro-
inflammatory signals into the surrounding tissue microenvironment that further recruits 
inflammatory cells and immune cells specialized for clearing necrotic debris (Hanahan and 
Weinberg, 2011). Sentinel immune cells, recruited leukocytes and even tumor cells, are 
also capable of releasing pro-inflammatory cytokines; soluble proteins that mediate cell-
to-cell communication (Chen et al, 2015). Cytokines are synthesized and released to 
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combat infection or tissue damage; however, these signaling molecules can have tumor 
promoting effects. Local fibroblasts and endothelial cells synthesize and release these 
proteins in response to inflammation. When fibroblasts remain activated, their signaling 
continues to work with other molecular pathways to promote neoplasm initiation in the 
TME. These activated fibroblasts are termed cancer-associated fibroblasts (CAFs) and are 
the most abundant cells in the breast cancer stroma (Soysal et al, 2015) (Wang et al 2017). 
Aside from recruiting immune cells, CAFs have an essential role in the promotion of 
metastasis and development of cancer through remodeling the ECM by inducing 
angiogenesis and directly stimulating cancer through hematopoietic growth factor (HGF), 
transforming growth factor beta (TGF- β), and platelet-derived-growth factor (Wang et al 
2017). This differs from normal fibroblasts, which typically combat cancer development.  
Angiogenesis, another hallmark of cancer development, is the formation of new 
blood vessels. In normal conditions, angiogenesis plays a role in wound healing and the 
female reproductive cycle and is regulated. In contrast to normal physiological conditions, 
during tumor progression an angiogenic switch is almost always activated and remains on, 
which results in continuous sprouting of new vessels that helps sustain tumor growth 
(Wang et al 2017). Similar to normal tissues, tumors require oxygen and nutrients from 
blood supply, and the ability to remove wastes and carbon dioxide; the tumor-associated 
neovasculature formed fulfills this need (Hanahan and Weinberg, 2011). Cancer-associated 
fibroblasts may promote tumor growth and invasion through release of fibroblast growth 
factor 2 (FGF2), and vascular endothelial growth factor (VEGF) into the TME. Pro-
angiogenic signals, like VEGF, are also secreted by cancer cells and many other cell types 
involved in the TME, including macrophages, platelets, adipose cells and keratinocytes 
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(Chen et al, 2015) (Wang et al, 2017). There are over a dozen proteins known to have 
angiogenic promoting and inhibiting effects and pro-angiogenic protein expression levels 
in cancer cells correspond to aggressiveness (Nishida et al, 2006). Induction of 
angiogenesis occurs early during the multi-stage development of invasive cancers, and 
once activated tumors display diverse patterns of neovascularization; the new blood vessels 
are abnormally leaky and inefficiently perfused in comparison to normal vasculature. As a 
result of these unusual and incomplete blood vessels, blood supply varies throughout the 
tumor and immune surveillance of the tumor is hindered, which also assists in evasion of 
host immune response (Hanahan and Weinberg, 2011). In addition, these newly formed 
blood vessels also provide cancer cells a pathway into systemic circulation which 
designates angiogenesis as a vital step in the development of metastatic cancer.  
Another critical component of the tumor microenvironment that greatly affects 
cancer progression is tumor hypoxia. Hypoxia occurs when tumor cells are exposed to a 
non-physiological level of oxygen tension and is a common factor in a majority of 
cancerous tumors (Muz et al, 2015). In normal conditions, tissues are in a state of normoxia 
if no complications are present. Due to structural and functional abnormalities of newly 
formed tumor vessels the diffusion of oxygen is limited, resulting in varying concentrations 
of oxygen throughout the tumor; diffusion of oxygen decreases as distance from the blood 
vessel increases (Gilkes and Semenza, 2013) (Liu et al, 2015). Other factors that can result 
in hypoxia include disease or treatment associated anemic reduction of oxygen transport. 
Reduction in intratumoral oxygen availability consequently suppresses tumor growth, 
slowing cell proliferation, which frequently leads to regions of necrosis in solid tumors. 
However, hypoxia can also promote tumorigenesis by altering expression of hypoxia-
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associated genes, changes in metabolism, and promotion of angiogenesis (Semenza, 2015). 
Given than there are varying levels of oxygen concentration throughout the TME, cancer 
cells throughout the tumor behave differently to decreased oxygenation. Normal cells in 
stressful conditions, like hypoxia, can activate autophagy, a metabolic and apoptotic 
adaption where intracellular organelles and proteins are captured, degraded and recycled 
in order to decrease oxidative metabolism and maintain homeostasis. Autophagy allows 
for the survival in short-term hypoxic conditions, but also has implications in the 
development of cancer. In some cases, this process acts as a suppressor to tumor growth, 
but in most contexts, tumorigenesis is promoted. Deficiencies in the microenvironment, as 
well as increased metabolic and biosynthetic demands, are likely causes of dependency on 
autophagy (Degenhardt et al, 2006) (Thermofisher, 2015). Within hypoxic tumor regions, 
basal autophagy is upregulated because it is vital for cell survival (Degenhardt et al, 2006). 
In breast cancer it is common to find Intratumoral hypoxia and approximately 25%-40% 
of invasive breast cancers exhibit hypoxic regions. Both hypoxic conditions and autophagy 
in cancer cells are driving TME conditions that are associated with more aggressive tumor 
phenotypes and increased risk of metastasis (Lundgren et al, 2007) (Muz et al, 2015) 
(Semenza, 2015). 
Tumor cells that are exposed to hypoxic conditions for longer periods of time are 
associated with a number of other characteristics that further the development of a more 
insidious disease. Prolonged exposure to low oxygen concentration in cancer cells are 
connected to increased genomic instability and mutagenesis, that potentially results from a 
higher frequency of DNA breaks, and an aggregation of DNA replication errors from 
hindered DNA repair systems. Due to higher mutation rates and rapid p53-dependent 
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apoptosis, an environment that selects for cells that can survive longer in these stressful 
conditions are selected for, especially after these cells experience reoxygenation (Muz et 
al, 2015). As unfit tumor cells and normal cells die off in the TME, the cells that do survive 
cycling hypoxia with sporadic reoxygenation periods are often more fit for proliferation 
and metastasis, further promoting cancer development, as well as more resistant to 
chemotherapy and radiation treatment (Liu et al, 2015). 
Hypoxic stress also influences changes in gene expression in both normal cells and 
cancer cells similarly apart from some key differences. In cancerous cells, this 
environmental pressure alters a number of complex intracellular signaling pathways 
involved in proliferation, survival, apoptosis, metabolism, migration, extravasation, and 
inflammation. In human cells, oxygen acts at the terminal electron acceptor in the process 
of oxidative phosphorylation and an adequate amount is needed in order to generate ATP. 
In particular, increasing the activity of hypoxia-inducible factors (HIFs) is a common 
response by both normal cells and cancer cells to decreased oxygen levels in order to 
regulate oxygen consumption among some of their other effects (Semenza, 2015). 
Adaptation to hypoxic conditions occurs through two transcription factors, HIF-1 and HIF-
2, which regulate the expression of over 1000 target genes (Semenza, 2012). Notably, HIF-
1 has been found to have a pivotal role in cancer cell adaptation to hypoxia and found to 
be elevated in solid tumors of the brain, colon, pancreas and breast cancers (Liu et al, 2015). 
HIF-1 is a heteromeric-dimeric transcription factor that consists of an oxygen regulated 
HIF-1α subunit and a constitutively expressed HIF-1β subunit (Wang et al, 1995). The 
HIF-1β is also known as the aryl hydrocarbon receptor nuclear translocator (ARNT), and 
both subunits contain basic-helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) domains 
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that partake in DNA binding and dimerization, respectively; both belong to the bHLH-PAS 
protein superfamily (Liu et al, 2015) (Wang et al, 1995). HIF-1α contains an oxygen-
dependent degradation (ODD) domain that regulates the stability and activity of the 
protein. This is achieved through hydroxylation by prolyl hydroxylase proteins of specific 
proline and asparagine residues in the presence of oxygen. Hydroxylation of the ODD is 
needed in order for the binding and ubiquitination by the von Hippel-Lindau protein, which 
targets the HIF-1α protein for degradation in the proteasome (Liu et al, 2015). Under 
hypoxic conditions, this hydroxylation is inhibited due to decreased levels of oxygen, 
which results in stabilization of HIF-1α, increased interaction with its co-activators, and its 
accumulation (Liu et al, 2015). As HIF-1α levels increase, the alpha and beta subunits 
hetero-dimerize leading to increased levels of HIF-1, resulting in increased transcription of 
HIF-1 associated genes. Since HIF-1β is normally produced in physiological conditions, 
HIF-1α can be considered the hypoxic-response element.  
Numerous HIF-1 target genes play a major role in many essential aspects of breast 
cancer biology. At diagnosis, high levels of HIF-1α are indicators of early relapse and 
metastasis, as well as related to poor clinical outcomes regarding human breast cancer 
patients (Liu et al, 2015). These target genes of HIF-1 are also upregulated in the TNBC 
subgroup (Gilkes and Semenza, 2013). Overexpression of these genes have crucial activity 
in cancer hallmarks, including angiogenesis, metabolic reprogramming, resisting 
apoptosis, invasion, and metastasis (Semenza, 2012). HIF-1 has emerged as a major target 
molecule of cancer therapy because it mediates many different mechanisms in cancer cells 
that are involved in metastasis and cancer severity. Understanding the molecular and 
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cellular mechanisms that fundamentally lead to metastasis, especially those in HIF-1 can 
be helpful in developing accurate prognoses and new treatment methods. 
Essentially, the initiation of metastasis consists of epithelial cells detaching from 
the primary tumor, adhering to and invading the surrounding stroma. The detachment of 
epithelial cells from primary tumors is thought of as the first step in metastasis and these 
cells undergo a transition process that resembles epithelial-mesenchymal transition (EMT) 
(Liu et al, 2015). HIF-1 upregulates EMT-associated transcription factors, or repressors, as 
well as activates signaling pathways associated with EMT that result in these cells losing 
epithelial phenotypical characteristics and obtaining mesenchymal cell-associated 
characteristics (Liu et al, 2015). Cellular and molecular characteristics such as absence of 
cell-to-cell adhesion, upregulation of vimentin, a mesenchymal protein, alteration of the 
cytoskeleton to promote flexibility, and increased motility are provoked by HIF-1 activity 
in tumor cells (Liu et al, 2015). In hypoxic microenvironments, these acquired 
characteristics promote the invasive ability of breast cancer cells that allow for metastasis.  
Following invasion of the stroma by these cells that underwent EMT, invasion of 
the connective tissue and intravasation into the bloodstream takes place if the complex 
process of metastasis continues. The two routes that are utilized by cancer cells to gain 
access to physiological circulation are lymphatic vessels and blood vessels (Gilkes and 
Semenza, 2013). To acquire access to the lymph or blood vessels, HIF-1 activates the 
transcription of genes that encode for proteases. Degradation or remodeling of the 
extracellular matrix within the primary tissue and at distant sites of metastasis are vital 
factors that allow for invasion and intravasation (Semenza, 2012). Specifically, proteases, 
termed matrix metalloproteinases (MMPs), are zinc-dependent endo-peptidases that 
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degrade many components of the extracellular matrix and surrounding basal membrane; 
MMP-2 and MMP-9 proteases are positively correlated to higher instance of breast cancer 
metastasis (Liu et al, 2015). Many studies suggest that HIF-1 further promotes the 
expression levels of MMP-2 and MMP-9 (Liu et al, 2015). HIF-1 also elicits the production 
of permeability factors VEGF and angiopoietin-2 (ANGPT2) that aid in the ability to 
intravasate, or pass into, the blood or lymph vessel (Semenza, 2012). Both VEGF and 
ANGPT2 induce angiogenesis and vascular modeling. Once cancer cells gain access to 
circulatory vessels, the ability to migrate to other tissues is enabled. If these cells are able 
to leave blood or lymph vessels, the disease itself may establish itself in other tissues and 
wreak havoc on the body.   
 Cancer cells that have entered circulation must leave, or extravasate from, the 
vessel in order to establish secondary tumors. Approximately less than 0.1% of cancer cells 
that enter circulation are able to produce a metastatic lesion (Liu et al, 2015). Traveling to 
distant tissues where cancer cells can then extravasate from the bloodstream is considered 
a limiting step in the metastasis process. This step is limiting because cells must first adhere 
to endothelial cells (ECs) in the vasculature, then disrupt the close interactions between 
these cells to extravasate into the distal tissue (Liu et al, 2015). A study that investigated 
metastasis of breast cancer to lung tissue revealed that HIF-1 promoted extravasation 
(Zhang et al, 2011). It was also found that HIF-1 induces the production of angiopoietin-
like 4 (ANGPTL4). Expression of ANGPTL4 in cancerous cells results in disruption of the 
vascular junctions between ECs, which increases the permeability of lung capillaries. 
Because of this, extravasation of cancer cells is facilitated into lung tissue, a common site 
of breast cancer metastasis (Padua et al, 2008). The TNBC cells that overexpress the HIF-
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1 protein, also show EC monolayer adherence in a HIF-1-dependent form. A direct target 
of HIF-1 transcription, L1 cell adhesion molecule (L1CAM) is a cell surface protein that 
plays a key role in mediating cell-cell adherence through homophilic and heterophilic 
interactions with integrins, neuropilin 1, or the CD24 cell surface receptor (Semenza, 
2012). Cancer cells that overexpressed L1CAM promoted adhesion of these cells to EC 
monolayers in vitro and revealed an increase in the number of cancerous cells that 
extravasated into lung tissue in mice (Zhang et al, 2011). These products of HIF-1 induced 
transcription, allow for the promotion of extravasation, providing cancer cells with the 
ability to invade distant tissues where they can establish metastatic sites.  
An emerging hallmark of cancer is reprogramming of cellular metabolism. 
Compared to healthy cells, cancer cells exhibit a higher energy demand due to rapid, 
increased cell proliferation, and varying available oxygen levels. Reprogramming 
metabolism is an essential biological process that provides a selective advantage for 
survival and growth by utilizing conventional metabolic pathways to generate energy and 
biosynthetic precursors, as well as maintain redox balance; Hypoxic conditions are capable 
of inducing metabolic alterations in tumor cells (Chen et al, 2015) (Muz et al, 2015). 
Normal cells under aerobic conditions, use glycolysis to break down glucose into pyruvate 
in the cytosol, which is further processed to CO2 in the mitochondria. When a cell is unable 
to obtain adequate amounts of oxygen for aerobic respiration, cells favor glycolysis in order 
to meet energy needs and very little mitochondrial oxygen-dependent activity takes place. 
Cancer cells, even in the presence of oxygen, can alter their metabolic activity, and 
consequently their production of energy, by limiting their glucose energy metabolism 
mostly to glycolysis. This state of cellular metabolism has been termed “aerobic 
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glycolysis” (Hanahan and Weinberg, 2011). The process of glycolysis alone is not 
sufficient for cellular survival, and cancer cells must make up for an approximate 18-fold 
ATP deficit afforded by glycolysis relative to oxidative phosphorylation (Hanahan and 
Weinberg, 2011). The hypoxia response system plays a key role in promoting the metabolic 
changes of cancer cells and acts pleiotropically to compensate for the loss of energy from 
mitochondrial function. Specifically, HIF-1 activity can upregulate the biosynthesis of 
glucose transporters to increase glucose uptake and glycolytic enzymes (Muz et al, 2015). 
Cancer cells also take advantage of glycolytic variability, which is also affected by HIF-1 
transcriptional activity. Other metabolic sources such as acetyl-CoEnzyme A, from fatty 
acid synthesis, and glutamine are utilized by cancer cells to combat hypoxic conditions 
(Hanahan and Weinberg, 2011).  
The HIF-1 protein is considered a master regulator of oxygen homeostasis and 
cancer development due to the transcriptional effects it produces. However, like any 
protein, the HIF subunits, specifically HIF-1α, can be subjected to post-translational 
modification (PTM) (Keith et al, 2011). In general, a protein can be modified at any time 
during a cell’s life cycle, but most PTM occurs shortly after modification. Various types 
of PTMs include phosphorylation, glycosylation, ubiquitination, S-nitrosylation, 
methylation, N-acetylation, lipidation, and proteolysis to name a few (Thermofisher, 2019). 
In order to achieve responsiveness to hypoxic conditions on a molecular level, an intricate 
and interlinked biochemical system involving both short-term modifications and reactions 
(no change in gene expression) and corresponding long-term alterations, such as changes 
in gene expression is integrated by cells (Semenza, 2017). These short-term responses can 
include changes in enzymatic activity that can regulate transcription factors by 
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posttranslational signaling events. Interestingly enough, the regulation of the HIF-1α 
protein is not impacted by hypoxia alone. These proteins also respond to various stressors, 
growth and coagulation factors, cytokines, hormones, each with different protein kinase 
regulated pathways, under normoxia (Semenza, 2017). As mentioned before, two bHLH-
PAS protein subunits form heterodimeric HIFs in hypoxic conditions (Wang et al, 1995). 
In terms of HIF regulated genes, response to hypoxia is highly dependent on the α subunits 
of HIFs (Keith et al, 2011). Thus, PTM of the HIF-1α subunit can yield differential effects 
on cellular functions.  
Many proteins that result in HIF-1α PTM regulate HIF-1 activity by either 
promoting or inhibiting interactions of HIF-1α with other proteins. Aside from 
hydroxylation, which is involved in HIF-1α degradation, the protein subunit is also 
subjected to an array of different oxygen-independent PTMs (Semenza, 2017). A vital 
PTM for protein activity and stability is phosphorylation. The phosphorylation of the HIF-
1α subunit can occur by direct or indirect kinase activity, but the overall extent to which 
this affects HIF-1 transcription varies based on the signal, cell-type, or tissue (Kietzmann 
et al, 2016). The PI3k/PKB (Akt) pathway is a major signaling node that is well known in 
tumorigenesis and can result in the indirect phosphorylation of the HIF-1α subunit 
(Thermofisher, 2015)) (Keith et al, 2011). One target of PKB(Akt) is glycogen synthase 
kinase-3 (GSK3), which can directly phosphorylate HIF-1α, inhibiting its activity. 
Phosphorylation of HIF-1α by GSK3 leads to interaction with F-box and WD protein 
(Fbw7) and Ubiquitin specific protease 28 (USP28) which systematically degrades the 
HIF-1α subunit (Keith et al, 2011). Yet, if GSK3 is phosphorylated by PKB(Atk), then 
HIF-1α remains unrestrained by its effects.  
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Another PTM that occurs to the HIF-1α protein that has drawn recent attention is 
O-Linked β-D-N-acetylglucosamine (O-GlcNAc) modification, or O-GlcNAcylation. O-
GlcNAc modification is involved in many crucial biological processes including 
transcription, translation, signal transduction and proteasomal degradation and has been 
found to be directly linked to pathological progression of chronic diseases, one of which is 
cancer (Ma and Hart, 2017). Whereas the glycosylation of proteins occurs between Asn-
linked (N-linked) or Ser/Thr-linked (‘mucin-type’ O-linked) cell surface and secreted 
proteins, O-GlcNAcylation is the covalent attachment of β-D-N-acetylglucosamine to the 
hydroxyl group on serine or threonine residues. This modification also almost solely occurs 
to proteins that are localized in the nucleus, mitochondria, and cytoplasm. Two enzymes, 
O-GlcNAc transferase (OGT) and β-D-N-acetylglucosaminidase (O-GlcNAcase), control 
this modification by addition and removal of the O-GlcNAc moiety, respectively. This 
allows for the reversibility and dynamicity of the process (Ma and Hart, 2014). In addition, 
O-GlcNAcylation can interact with other PTMs, including competitive or reciprocal 
activity with phosphorylation, and has been found to have implications in breast cancer 
patient outcomes (Ferrer et al 2014). 
The importance of investigating O-GlcNAc modification lies within its effects on 
cancer cells and the influences it has in the progression of the disease. Although the 
mechanism that results in elevated O-GlcNAcylation is not completely understood, the 
elevated levels of OGT have been observed in breast, prostate, and lung cancer. Decreased 
levels of OGA have been seen in breast and colon cancers as well (Ferrer et al 2014). Breast 
cancer cells containing high HIF-1α levels were observed to have had a heightened 
occurrence of O-GlcNAcylation with elevated OGT levels. Lower levels of OGA in these 
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cells also correlated with poor patient outcome. The process of O-GlcNAcylation regulates 
metabolic reprogramming in cancer cells through the regulation of HIF-1α. Both OGT and 
O-GlcNacylation are suggested to play key roles in maintenance of aerobic glycolysis, by 
increasing HIF-1α stabilization and promoting aerobic glycolysis in a feed-forward 
mechanism. Elevation of this PTM was also observed to protect breast cancer cells from 
endoplasmic reticulum stress-mediated apoptosis. The process of O-GlcNAc modification 
also competes with HIF-1α phosphorylation, which affects GSK3/Fbw7/USP28-dependent 
degradation, allowing for continuation of its transcriptional effects on cancer cells (Ferrer 
et al 2014) (Ma and Hart, 2014). Due to its influence on multiple hallmarks of cancer, O-
GlcNacylation has proven to be a promising therapeutic target that can effectively combat 
cancers that benefit from it.  
Over the span of about 30 years, there have been a number of approaches that have 
been developed for O-GlcNAcylated protein analysis. Recently, mass spectroscopy (mass 
spec) has emerged as one alternative to detect this modification. In contrast to biochemical 
detection methods, such as galactosyltransferase-catalyzed labeling followed by 
autoradiography or immunoblotting with specific antibodies, mass spec has provided a 
unique capacity for the deduction of O-GlcNAc modification in proteins in a site-specific 
and semi-quantitative manner (Ma and Hart, 2017). There have been many methods that 
have been applied to the detection of this modification, each using alternative 
fragmentation methods. Three of these methods include collision-induced fragmentation 
(CID), higher energy collision dissociation (HCD), and electron transfer dissociation 
(ETD). Mass Spectrometry-based identification is an especially powerful tool, but it cannot 
independently differentiate between O-GlcNAc and O-GalNAc without highly specific 
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approaches, such as labeling techniques (e.g., antibodies specific for the molecule). In order 
to confirm the status of specific modifications on proteins, techniques such as Western 
blotting can be used as a confirmation tool (Ma and Hart, 2017).  
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Materials and Methods 
 
Cell Culture/Compound Treatment 
 Human breast tumor cell line MDA-MB-231-derived subclone BoM1833 (BoM, 
bone metastatic, Massagué, 2003) cells, developed by the Massagué group at Memorial 
Sloan Kettering Cancer Center (New York City, NY), were maintained in RPMI1640 
medium (GIBCO) supplemented with 10% (v/v) fetal bovine serum (FBS) (Hyclone) and 
0.5% penicillin/streptomycin (p/s) (equivalent to 50 units mL-1 and 50 µg mL−1, 
respectively) (Life Technologies) in a humidified environment at 37 °C under 5% 
CO2/95% Air. The cells were grown on 10 cm tissue culture plates (USA Scientific). To 
isolate nuclear extracts, BoM cells were plated at the density of 10 x 106 cells/plate onto 
10 cm plates.  After overnight incubation, 1,10-phenanthroline (Phen) (Sigma Aldrich) was 
added to the cells in a volume of 10 μL (10 mM stock solution in DMSO)/plate to achieve 
the final concentration of 10 μM (7 plates), and O-(2-acetamido-2-deoxy-D-
glucopyranosylidenamino)-N phenylcarbamate (PUGNAc) (Sigma Aldrich) in a volume 
of 30 μL (10 mM stock solution in DMSO)/plate to achieve the final concentration of 30 
μM (7 plates). 
Following 4-hour incubation of the compounds with the BoM Cells, aspiration of 
the conditioned media then took place, and the plate was washed once with cold 1x 
Dulbecco’s Phosphate Buffered Saline (DBPS), diluted from 10x DPBS (Sigma Aldrich 
D1408). Subsequent detachment of the cells was accomplished by the addition of 
0.9mL/plate of 0.25% trypsin ethylenediaminetetraacetic acid (Trypsin-EDTA) solution 
(Gibco 25200-056), at 37 °C for five minutes. The trypsin reaction was stopped with the 
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addition of 10 mL 10% FBS RPMI1640 Media. The cell suspension was transferred to a 
15 mL centrifuge tube, and the pellet was collected after centrifugation at 500 rpm for five 
minutes at room temperature.  
 
Cytoplasmic and Nuclear Extract Preparation: 
 The pellet was washed once with 10 mL cold 1x DPBS and collected by 
centrifugation at 500 rpm for five minutes. The cell pellet was then resuspended in 1x 
DPBS, transferred to a 1.5 mL microcentrifuge tube, and pelleted by centrifugation at 800 
rpm (100 x g) for three minutes. The supernatant was removed, leaving the cell pellet as 
dry as possible in the microcentrifuge tube. Ice-cold cytoplasmic extract reagent (CER) I 
(950 μL) was then added to the cell pellet and vortexed for 15 seconds. Incubation of the 
tube on ice for 10 minutes followed. After chilling, 55 μL of CER II was added to the tube 
and vortexed for five seconds (16,000 x g). The cell lysate was centrifuged at 16,000 x g 
for five minutes at 4 °C. The supernatant and pellet produced from this step are the 
cytoplasmic extract and the nuclei pellet, respectively. 
Immediately after, the supernatant was transferred to a pre-chilled tube, and the 
tube containing the pellet was supplemented with ice-cold nuclear extract reagent (NER) 
(475 μL) to lyse the nuclei. The nuclear lysate was then vortexed for 15 seconds and chilled 
for 10 minutes for a total time of 40 minutes; four cycles of centrifugation (16,000 x g) for 
10 minutes. The supernatant (nuclear extract sample) was transferred to a new tube. Both 
nuclear and cytoplasmic extract samples were aliquoted to new tubes respective to the 
following: NE 5 μL(1x); 15 μL (2x); ~150 μL (1x); remaining NE ~350 μL and CE 5 
μL(1x); 20 μL (1x); 100 μL (1x); 200 μL (2x); remaining CE~500 μL. The production of 
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cellular extracts from Phen and PUGNAc BoM cells yielded 4 distinct extracts: NE+Phen, 
NE+PUGNAc, CE+Phen, and CE+PUGNAc.  
 
Protein Concentration and Quantification:  
 Analysis and standard comparison of BoM cytoplasmic and nuclear extracts to 
determine protein concentration was accomplished by utilizing a micro BCA protein assay 
kid (ThermoFisher Scientific 23235). The series of standards was made using a 
micropipette to transfer set volumes of 2 mg/mL bovine serum albumin (BSA) and distilled 
deionized (dd) water into eight separate 0.5 mL tubes (shown in table 1). Tubes A and B 
were produced first by creating two diluted BSA solutions with concentrations of 40μg/mL 
and 30μg/mL respectively. Thereafter, diluted BSA solutions of concentrations (μg/mL) of 
20, 15, 10, 7.5, 5, and 0 were made by transferring 150 μL of the respective BSA solution 
to the next ordered tube that would result in a BSA solution of half that concentration (tubes 
B through J).  
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Table 1. Micro BCA protein concentration standards prepared for protein concentrations 
assay (BSA standard at 2mg/mL) 
 
Tube 
 
dd H2O added 
 
BSA vol added 
 
Final Concentration 
A 490 μL 10 μL 40 μg/mL 
B 394 μL 6 μL  30 μg/mL 
C 150 μL 150 μL from 
dilution A 
20 μg/mL 
D 150 μL 150 μL from 
dilution B 
15 μg/mL 
E 150 μL 150 μL from 
dilution C 
10 μg/mL 
F 150 μL 150 μL from 
dilution D 
7.5 μg/mL 
G 150 μL 150 μL from 
dilution E 
5 μg/mL 
H 150 μL 0 μL 0 μg/mL 
 
Following the production of the standards, an array of protein concentrations was 
made in eight separate tubes by using diluted NE and CE samples. By using the BoM 
cellular extracts, (Phen+NE, PUG+NE, Phen+CE, and PUG+CE) dilutions were prepared 
for placement in a 96-well plate. The NEs and CEs were then made into two different 
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dilutions resulting in eight total solutions. Four different 1:40 dilutions were produced by 
diluting the sample in tubes. Each 1:40 dilution that was produced was composed of 2.5 
μL of protein sample and 97.5 μL of dd water respective to 100 μL. The dilutions were 
then pipetted into different wells on the plate. From the corresponding tubes of 1:40 
dilution solutions, four 1:80 dilutions were produced by adding 50 μL of the 1:40 dilutions 
to 50 μL of dd water in separate tubes. These dilutions consisted of column 11 on the well 
plate shown on table 2. Filling column 12 of the 96-well plate was completed by transfer 
and dilution of the respective NE or CE extracts in column 11. Following production of the 
array of protein concentrations, 100 μL of each standard was added to individual wells on 
column 10 of a 96-well plate. 
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Table 2. BoM cell BCA protein concentration assay: 96-well plate layout 
  10 11 12 
A  0 μg/mL 
(100μL) 
Phen NE 
(1:40) 
 Phen NE 
(1:100) 
B 5 μg/mL 
(100μL) 
Phen CE 
(1:40) 
 Phen CE 
(1:100) 
C 7.5 μg/mL 
(100μL) 
PUGNAc NE 
(1:40) 
PUGNAc NE 
(1:100) 
D 10 μg/mL 
(100μL) 
PUGNAc CE 
(1:40) 
PUGNAc CE 
(1:100) 
E 15 μg/mL 
(100μL) 
Phen NE 
(1:80) 
Phen NE 
(1:100) 
F 20 μg/mL 
(100μL) 
Phen CE 
(1:80) 
Phen CE 
(1:100) 
G 30 μg/mL 
(100μL) 
PUGNAc NE 
(1:80) 
PUGNAc NE 
(1:100) 
H 40 μg/mL 
(100μL) 
PUGNAc CE 
(1:80) 
PUGNAc CE 
(1:100) 
 
A working solution was then prepared by mixing 36 μL of BCA reagent C, 864 μL 
of BCA reagent B, and 900 μL of BCA reagent A (1:24:25 ratio), of which 100 μL was 
added to each well and mixed well. After preparation of the three columns on the 96-well 
plate, the plate was incubated at 37 °C for two hours. Following this two-hour period, the 
plate was then analyzed using the SPECTRAFluor Plus and read at 562nm. 
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Coupling of the HIF antibody to the resin 
The purpose of using immunoprecipitation (IP) was to isolate and purify the HIF-
1α protein so that it may be used for mass spectroscopy. Preparation for IP began with 
cross linking the primary anti-HIF-1α antibody (BD Transduction Laboratories: cat: 
610959, Lot: 06820, 250 μg/mL) to the protein A/G agarose bead using a commercial kit 
(Pierce, cat: 26147).  
A 2 mL of 1x coupling buffer was made by diluting 100 μL of 20x of coupling 
buffer with 1900 μL of water (QIAGEN 1017879). The Pierce Protein A/G Plus Agarose 
(20 μL) was then placed into a Pierce spin column and centrifuged at 1000 x g for one 
minute. The prepared Coupling Buffer was then used to wash the resin and centrifuged 
once more. Following this step, 10 μg of antibody for coupling was made by preparing 10 
μL of antibody (Ab), 5 μL of 20 x Coupling Buffer, and 85 μL of dd water. The prepared 
solution was then added to the column containing the resin.  
Preparation for the crosslinking of the antibody began with adding 217 μL dimethyl 
sulfoxide (DMSO) to 25 mM disuccinimidyl suberate (DSS) to make a 1:10 dilute solution 
of 2.5mM DSS. Following, 2.5 μL of 20x Coupling Buffer, 9 μL of 2.5 mM DSS, and 38.5 
μL of distilled deionized (dd) water was added to the column to initiate the coupling 
reaction and incubated for 50 minutes on a rotator. Once reacted, 50 μL of elution buffer 
was used to wash the solution twice to remove any non-crosslinked antibodies and halt the 
reaction. This solution was then washed twice with 200 μL of cold IP Lysis/Wash Buffer 
and centrifuged after each washing. The final product of this procedure was then used in 
the IP process to isolate the purified HIF-1α protein. 
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Immunoprecipitation 
In preparation of IP, 330 μL of Phen treated BoM cell NE and 295 μL of PUGNAc 
(referred to as PUG in this procedure) treated BoM NE were washed with IP Lysis (170 
μL and 205 μL, respectively to make volume consistent). Both of the extracts were then 
incubated overnight at 4 °C. Following incubation, the extracts were placed in separate 
columns, the bottom plug was removed, and the screw cap was removed. The columns 
were then placed in a collection tube and centrifuged for one minute at 1000 x g; the flow 
through was saved (Phen elute 1 and PUG elute). Following this step, 200 μL of lysis wash 
was added and rotated once more, twice. Next, 100 μL of 1x conditioning buffer (2.15 μL 
100x and 212.85 μL dd water) was used to wash the samples before placement into new 
tubes with 10 μL of elution buffer before centrifugation at 1000 x g for five minutes. After 
spinning, 50 μL of elution buffer was added once more before another five minutes of 
rocking. 
Following removal from the centrifuge, the “elute” from each extract was 
transferred to a new tube and stored on ice (Phen elute 2 and PUG elute 2). The columns 
were then regenerated with 100 μL of 1x coupling buffer, and rotated, which was repeated 
once. A new bottom plug was then used, and the bottom was wrapped up after 250 μL of 
1x coupling buffer was added to each column. The sample was then put into 15 mL tubes 
and stored at 4 °C (Phen NE and PUG NE). The products obtained from this procedure 
were then prepared for separation by SDS-PAGE and are as followed: Phen NE, Phen elute 
1, Phen Elute 2, PUG NE, and PUG elute 2. These samples, a molecular weight marker 
(Bio-Rad, Kleidoscope, 161-0324 (discontinued)), and the “Ab” Phen, “Ab PUG” were 
then prepared for loading onto the gel. The last two lanes on the right of the SDS page were 
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filled with the left-over pellet from the columns. In lane nine and lane ten, 4 μL of 5x 
sample buffer and 16 μL of sample of Phen and PUG were added, respectively (not shown 
in table 3). These solutions were mixed and then boiled for five minutes to denature 
proteins. After, the samples were put on ice and the sample was collected through a quick 
spin. 
 
Table 3. Layout for SDS-PAGE sample preparation 
Lane 
number 
1 2 3 4 5 6 7 8 
Sample 
type 
Mw Phen NE Phen 
Elute1 
Phen 
Elute2 
PUG 
NE 
PUG 
Elute 
“Ab” 
Phen 
“Ab” 
PUG 
5x 
Sample 
Buffer 
(μL) 
4 4 4 4 4 4 4 4 
Sample 
(μL) 
10 15 3 3 15 3 16 16 
dd H2O 
(μL) 
6  13 13  13   
  
 
SDS-PAGE and Western Blot 
The samples prepared from the IP procedure were loaded onto a Bio-Rad precast 
gel (Mini-protean TGX, 4-20%, 456-1094) (order shown on table 3). A 1x Tris/ 
tricine/SDS buffer, prepared by diluting the 10x buffer solution (Bio-Rad 161-0744) with 
180 mL of dd water, was then added to the electrophoresis apparatus. The molecular weight 
marker was then loaded into the first lane, followed by the loading of samples (left to right 
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in table 3) in the rest of the gel lanes respectively. The gel was run at 125 V for 45 minutes, 
then transferred from the SDS-PAGE gel to a dd water prewet nitrocellulose membrane. 
This was achieved by soaking the gel in 1x transfer buffer, composed of 100 mL of 10x 
TG (Bio-Rad 161-077), 100 mL of methanol (HPLC Grade, Fisher A 452-4), and 800 mL 
of dd water, the transfer sandwich assembled, and for 50 minutes at 140 mA. An ice pack 
was placed outside the apparatus to assist with temperature control. The transfer apparatus 
was placed on a stir plate with a stir bar to aid in solution mixing. After transfer, Ponceau 
S. Solution (Sigma Aldrich) was used to stain the proteins on the nitrocellulose membrane 
to ensure the transfer is effective 
For Western blot, a Tween-Tris buffered solution (TTBS) was prepared by diluting 
0.25 mL of tween 20 (Sigma Aldrich, P1379) and 50 mL of 10x Tris Buffered Saline 
(Boston Bioproducts, BM-301) with 450 mL of dd water.  The blocking solution was 
prepared by dissolving 4.8g of non-fat dry milk (blotting-grade blocker, Bio-Rad 170-
6404) into 96 mL of TTBS.  The membrane was incubated with the 5% non-fat dry milk 
TTBS solution for an hour with rocking at room temperature, to prevent non-specific 
antibody binding to the membrane. The membrane was then washed twice with TTBS (5 
minutes each, rocking, room temperature). Following the washes, the primary HIF-1α 
antibody (BD Transduction Laboratories: cat: 610959, Lot: 06820, 250 μg/mL) was added 
at the dilution of 1:1000 in the blocking solution and the incubation continued for another 
hour.  The membrane was then washed twice with 5% non-fat milk/TTBS solution (5 
minutes each, rocking, room temperature). The secondary antibody, a stabilized goat-anti-
mouse HRP-conjugated antibody (PIERCE, cat: 1858413, Lot: HH 10648, 10 μg/mL) was 
added to the blocking solution at 1:3000 dilution (3 μL to 9 mL of 5% milk/TTBS). After 
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an hour, the membrane was washed once for 10 minutes with TTBS followed by two 
washes for 5 minutes each with TTBS. The membrane was then developed with West 
Femto Maximum Sensitivity Substrate (Thermo 430951) and imaged on a Bio-Rad 
ChemiDoc™ Imaging System.  
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Results/Discussion 
 Previous research from our group has established the conditions that induced the 
O-GlcNAcylation of HIF-1α protein in breast cancer cells. To further investigate the role 
of this PTM in HIF biology and oxygen homeostasis, it is important to identify the amino 
acid residue(s) that is/are subjected to this modification. A combined approach that 
incorporates cell biology and mass spectrometry was applied to isolate HIF-1α protein and 
identify the O-GlcNAcylated site(s). Following treatment with 1,10-phenanthroline and 
PUGNAc, nuclear, and cytoplasmic extract samples were prepared from BoM cells and the 
protein concentrations were determined by the BCA method. The following table was 
acquired from the SPECTRAFluor Plus, a fully automatic, computer-controlled 
fluorescence, absorbance and luminescence instrument used to analyze microplate 
samples. The values obtained are characterized by light absorbance measured at 562 nm. 
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Table 4. Light absorption in 562 nm of micro BCA protein concentration assay of BoM 
nuclear and cytoplasmic extracts. 
 10 11 12 
A 0.104 1.985 0.347 
B 0.183 0.747 0.269 
C 0.207 1.895 0.527 
D 0.240 0.639 0.296 
E 0.310 0.239 0.401 
F 0.380 0.37 0.362 
G 0.562 0.696 0.378 
H 0.583 0.546 0.060 
 
 By using a line of best fit, derived from the slope of the standard values, the protein 
concentrations of nuclear extracts and cytoplasmic extracts were determined: 
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Figure 1. Standard curve from micro BCA protein concentration assay of BoM nuclear and 
cytoplasmic extracts.  
 
 A line of best fit, that was determined from the standard curve, had the linear 
formula y = 0.0668x - 0.0876; The x and y value represent the protein concentration and 
absorbance respectively. The formula was then used to calculate the protein concentration 
from the respective absorption data. These values that correspond with their dilution, either 
1:40 or 1:80, were then multiplied by 40 and 80 to obtain the original protein concentration. 
The same method was used for the 1:100 dilutions. Protein concentration values obtained 
from the standard curve linear trendline equation are shown in table 5 and correspond with 
the data in Table 2 and Table 4. 
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Table 5. Protein concentration calculated using the standard curve trendline equation (y = 
0.0668x - 0.0876). 
 10 11 12 
A 1.311 - 4.949 
B 2.494 - 3.781 
C 2.853 - 7.644 
D 3.347 - 4.186 
E 4.395 3.332 5.575 
F 5.443 5.293 5.174 
G 8.167 - 5.413 
H - 7.928 0.653 
 
Protein concentration values that correspond with absorbances above 0.583 nm (40 
μg/mL) were not utilized in data calculation. This is because the extrapolate will be 
unreliable. This data indicates that nuclear extracts of both Phen and PUGNAc treated BoM 
cells contain higher concentration levels of HIF-1α protein compared to the cytoplasmic 
extracts. However, another separate protein concentration assay should be conducted in 
order to confirm concentration values to ensure that they are reliable. 
To enhance the purity of HIF-1α protein from the immunoprecipitation, the anti- 
HIF-1α antibody was conjugated to the protein A/G beads by crosslinking using a 
commercial kit. The HIF-1α protein isolated from the IP procedure was analyzed by 
Western blot. Both the nuclear extract samples and the elutes from the columns were 
subjected to SDS-PAGE separation followed by Western blot. 
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Figure 2. Western blot analysis of HIF-1α in nuclear and cytoplasmic extracts 
 
 The molecular weight marker was loaded into lane one, and no band appeared 
because the marker does not contain HIF-1α proteins. Lanes two through four contained 
the Phen NE, the first Phen NE elute, and the second Phen NE elute, followed by PUG NE 
and PUG Elute into lanes five and six, Phen “Ab” and PUG “Ab” into lanes seven and 
eight, and finally Phen o/n and PUG o/n into the nine and ten lanes. After visualization, it 
was determined that the results from the Western Blot Analysis of HIF-1α were not as 
expected. Specifically, we were not able to purify HIF-1α protein in this effort. 
The appearance of the bands shown in the elute lanes indicated the presence of 
antibodies. Ineffective conjugation of the antibody to the protein A/G agarose bead would 
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result in the separation of non-crosslinked HIF-1α antibody from the column after 
centrifugation. This could also indicate that there is an absence of the HIF-1α protein in the 
lane, which could be accounted to the failed antibody conjugation to the bead. This could 
also be why the IP lanes do not have much protein. The longer bands shown on the Western 
blot may have been caused by degradation of the HIF-1α protein. If HIF-1α was degraded, 
then antibodies would not be able to interact with the protein and no distinct bands would 
appear. The weak bands may also appear because the crosslinking of antibody to column 
was not effective and some of the antibody might not have been bound or were detached. 
The BoM cells were treated with PUGNAc in order to raise O-GlcNAc levels. In 
addition, treatment of BoM cells with 1,10-phenanthroline was used as a control to ensure 
the induction of HIF-1α protein. Both treatments of the NE samples were expected to 
present HIF-1α bands in the Western blot. If the procedure had produced the results 
expected, mass spectroscopy would be utilized in order to analyze HIF-1α protein samples 
to detect O-GlcNAcylation. Even though the first round of this experiment did not turn out 
as expected, it has laid a foundation for continuation of the project. 
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Conclusion and Future Perspective 
 There are many anticancer drugs that are aimed at specific molecular targets 
responsible for, in one way or another, enabling particular capabilities. However, targeting 
one key pathway may not completely disable a hallmark ability, allowing for the possibility 
of some cancer cells to survive and eventually adapt to the pressure applied by therapeutic 
measures. This ultimately sheds a light on the importance of exploring the therapeutic 
targeting of specific biomolecules that influence multiple hallmarks of cancer. Specifically, 
the HIF-1α protein subunit, has key roles in the acquisition of multiple hallmark abilities 
that promote cancer development and survival. As these subunits increase in concentration 
in cancer cells, more heterodimeric HIFs form, which induces transcriptional activity that 
allows for metabolic reprogramming, and promotes other hallmarks including, resisting 
cell death, angiogenesis, and invasion and metastasis. Having a primary effect on the 
intracellular regulation of HIF-1α in breast cancer cells, O-GlcNAcylation, which stabilizes 
the protein subunit and allows for maintenance of its transcriptional effects, has been 
correlated to negative prognoses in these patients. The implications that the process of O-
GlcNAcylation has on the regulation of HIF-1α and outcomes of breast cancer patients has 
drawn attention to exploration of therapeutic targeting. Although the results were not as 
expected, the completion of this specific procedure for the first time in hopes of 
establishing usable samples for mass spectroscopy has laid a basis for future endeavors 
regarding the detection of O-GlcNAcylation in HIF-1α proteins.   
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